Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates
Rhea-AI Summary
Stereotaxis (NYSE: STXS) reported 2026 second quarter revenue of $7.7 million, down from $8.8 million a year earlier, with systems revenue at $1.5 million and recurring revenue at $6.2 million. Robotic catheter revenue surpassed $1 million, growing 270% sequentially, supported by initial Synchrony digital operating room sales following FDA clearance in April.
Gross margin was 58%, including 66% on recurring revenue and 29% on systems. Operating expenses were $9.1 million, including $2.5 million of non-cash charges, resulting in a net loss of $4.5 million. Negative free cash flow was $3.7 million. At June 30, 2026, the company held $10.5 million in cash and had no debt. Stereotaxis completed its previously announced acquisition of Robocath and reported the first U.S. purchase of a GenesisX robotic system, expected to be installed this fall.
Positive
- Robotic catheter revenue exceeded $1M, up 270% sequentially in Q2 2026
- Recurring revenue rose to $6.2M from $5.8M in Q2 2025
- Recurring gross margin remained strong at 66% in Q2 2026
- Cash and cash equivalents were $10.5M with no debt at June 30, 2026
- Completed acquisition of Robocath, expanding endovascular robotics portfolio
- Recorded first U.S. purchase of a GenesisX robotic system and initial Synchrony sales
Negative
- Total revenue declined to $7.7M from $8.8M in Q2 2025
- Systems revenue fell to $1.5M from $3.0M year over year
- Net loss widened to $4.5M from $3.8M in Q2 2025
- Operating expenses increased to $9.1M from $8.6M year over year
- Negative free cash flow was $3.7M, similar to prior year
- Accumulated deficit increased to $593.7M at June 30, 2026
Market Reaction – STXS
Following this news, STXS has declined 1.35%, reflecting a mild negative market reaction. Argus tracked a trough of -3.7% from its starting point during tracking. Our momentum scanner has triggered 6 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $1.44.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Q1 earnings report | Negative | -3.6% | Revenue declined year over year while FDA milestones and 2026 guidance were reiterated. |
| Mar 09 | FY earnings report | Positive | -4.8% | Annual revenue grew 20% and management reiterated 2026 revenue above $40M. |
| Nov 11 | Q3 earnings report | Positive | -14.7% | Revenue grew year over year alongside new clearances and early catheter commercialization. |
| Aug 07 | Q2 earnings report | Positive | +14.2% | Revenue grew 95% year over year and MAGiC Sweep received FDA clearance. |
| May 12 | Q1 earnings report | Positive | +1.9% | Revenue increased 9% year over year with ongoing regulatory reviews and commercialization. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The five tag-matched earnings events showed three divergences and two alignments, including negative reactions after several positive or mixed releases.
Key Terms
robotic catheter medical
endovascular intervention medical
mark-to-market adjustment financial
convertible preferred stock financial
contingent consideration financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Robotic catheter revenue surpasses
$1M in the quarter, growing270% sequentially - First GenesisX robotic system purchase by US hospital to be installed this fall
- Multiple Synchrony digital operating room systems sold and installed following FDA clearance in April
- Completed previously announced acquisition of Robocath, strengthening robotic technology leadership across the full spectrum of endovascular procedures
ST. LOUIS, Mo., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial results for the second quarter ended June 30, 2026.
“Stereotaxis has reached an important commercial inflection point. Following years of product development and regulatory milestones, the Company’s expanded robotic platform is now generating accelerating commercial adoption across multiple product lines,” said David Fischel, Stereotaxis Chairman and CEO. “Over the last several years we advanced an exciting ecosystem of robotic, catheter and digital innovations through development and regulatory milestones. We are now witnessing the initial green shoots of commercial success, including quarterly revenue from our novel robotic catheters exceeding one million dollars, the first Synchrony system sales, and the first US purchase of a GenesisX robot.”
“We are making methodical progress on the operational and commercial efforts needed to drive revenue growth. We expect continued momentum throughout this year as we ramp manufacturing and address commercial friction. We have line of sight to sustained revenue growth and reaching cash flow profitability in the coming quarters.”
“In parallel to our commercial efforts, we continue to invest in a broad pipeline of innovations that expand our technology into a platform across endovascular surgery, enhances our competitiveness in electrophysiology, and delivers digital connectivity, automation and intelligence to the operating room.”
2026 Second Quarter Financial Results
Revenue for the second quarter of 2026 totaled
Gross margin for the second quarter of 2026 was
Operating loss and net loss in the second quarter of 2026 were (
Cash Balance and Liquidity
At June 30, 2026, Stereotaxis had cash and cash equivalents of
Forward Looking Expectations
Stereotaxis anticipates recurring revenue to grow to approximately
Stereotaxis believes it can advance its strategy, integrate Robocath, and grow revenue significantly without having to subject investors to substantial dilution. Cash flow profitability is anticipated to be reached in the first half of 2027.
Conference Call and Webcast
Stereotaxis will host a conference call and webcast today, August 11, 2026, at 4:30 p.m. Eastern Time. To access the conference call, dial 800-715-9871 (US and Canada) or 646-307-1963 (International) and give the participant pass code 4404741. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at www.Stereotaxis.com.
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. These forward-looking statements include without limitation statements regarding the recently completed acquisition of Robocath, including the Company’s ability to advance its strategy, integrate Robocath, and grow revenue significantly without having to subject investors to substantial dilution. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involving the following: the Company’s ability to manage expenses at sustainable levels; acceptance of the Company’s products in the marketplace; the effect of global economic conditions, including tariffs, on the ability and willingness of customers to purchase its technology; competitive factors; changes resulting from healthcare policy; dependence upon third-party vendors; timing of regulatory approvals, including as it relates to Robocath’s products; the impact of pandemics or other disasters; statements generally relating to our recent acquisition of Robocath, including any benefits expected from the acquisitions, as well as any plans, forecasts and other expectations with respect to Robocath’s business following the completion of the transaction; and the other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission.
By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Additional information will also be set forth in future filings that we make with the SEC from time to time. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
Company Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly R. Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
| Stereotaxis, Inc. | ||||||||||||||||||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||||||||
| (in thousands, except share and per share amounts) | Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| Revenue: | ||||||||||||||||||||||||||
| Systems | $ | 1,479 | $ | 3,038 | $ | 2,798 | $ | 5,002 | ||||||||||||||||||
| Disposables, service and accessories | 6,191 | 5,760 | 11,163 | 11,268 | ||||||||||||||||||||||
| Total revenue | 7,670 | 8,798 | 13,961 | 16,270 | ||||||||||||||||||||||
| Cost of revenue: | ||||||||||||||||||||||||||
| Systems | 1,057 | 2,366 | 1,861 | 4,033 | ||||||||||||||||||||||
| Disposables, service and accessories | 2,127 | 1,853 | 3,820 | 3,594 | ||||||||||||||||||||||
| Total cost of revenue | 3,184 | 4,219 | 5,681 | 7,627 | ||||||||||||||||||||||
| Gross margin | 4,486 | 4,579 | 8,280 | 8,643 | ||||||||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||||
| Research and development | 2,390 | 1,777 | 4,787 | 4,127 | ||||||||||||||||||||||
| Sales and marketing | 2,595 | 3,269 | 5,212 | 6,417 | ||||||||||||||||||||||
| General and administrative | 4,069 | 4,002 | 8,830 | 8,497 | ||||||||||||||||||||||
| Other | - | (492 | ) | - | (492 | ) | ||||||||||||||||||||
| Total operating expenses | 9,054 | 8,556 | 18,829 | 18,549 | ||||||||||||||||||||||
| Operating loss | (4,568 | ) | (3,977 | ) | (10,549 | ) | (9,906 | ) | ||||||||||||||||||
| Other income | - | (1 | ) | (5 | ) | (1 | ) | |||||||||||||||||||
| Interest income, net | 100 | 152 | 225 | 258 | ||||||||||||||||||||||
| Net loss | $ | (4,468 | ) | $ | (3,826 | ) | $ | (10,329 | ) | $ | (9,649 | ) | ||||||||||||||
| Cumulative dividend on convertible preferred stock | (314 | ) | (318 | ) | (625 | ) | (632 | ) | ||||||||||||||||||
| Net loss attributable to common stockholders | $ | (4,782 | ) | $ | (4,144 | ) | $ | (10,954 | ) | $ | (10,281 | ) | ||||||||||||||
| Net loss per share attributed to common stockholders: | ||||||||||||||||||||||||||
| Basic | $ | (0.05 | ) | $ | (0.05 | ) | $ | (0.11 | ) | $ | (0.12 | ) | ||||||||||||||
| Diluted | $ | (0.05 | ) | $ | (0.05 | ) | $ | (0.11 | ) | $ | (0.12 | ) | ||||||||||||||
| Weighted average number of common shares and equivalents: | ||||||||||||||||||||||||||
| Basic | 100,031,760 | 87,952,086 | 99,496,942 | 87,861,231 | ||||||||||||||||||||||
| Diluted | 100,031,760 | 87,952,086 | 99,496,942 | 87,861,231 | ||||||||||||||||||||||
| STEREOTAXIS, INC. | |||||||
| CONSOLIDATED BALANCE SHEETS | |||||||
| (in thousands, except share amounts) | June 30, 2026 | December 31, 2025 | |||||
| (Unaudited) | |||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 10,491 | $ | 13,421 | |||
| Accounts receivable, net of allowance of | 7,549 | 5,847 | |||||
| Insurance receivable | 6,316 | 4,316 | |||||
| Inventories, net | 12,520 | 9,567 | |||||
| Prepaid expenses and other current assets | 1,111 | 698 | |||||
| Total current assets | 37,987 | 33,849 | |||||
| Property and equipment, net | 2,881 | 3,019 | |||||
| Goodwill | 3,764 | 3,764 | |||||
| Intangible assets, net | 5,957 | 6,429 | |||||
| Operating lease right-of-use assets | 4,658 | 4,912 | |||||
| Prepaid and other non-current assets | 335 | 278 | |||||
| Total assets | $ | 55,582 | $ | 52,251 | |||
| Liabilities and stockholders' equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 6,866 | $ | 4,768 | |||
| Accrued liabilities | 1,325 | 2,065 | |||||
| Accrued legal liabilities | 6,316 | 4,316 | |||||
| Deferred revenue | 5,928 | 5,675 | |||||
| Current contingent consideration | 5,673 | 4,894 | |||||
| Current portion of operating lease liabilities | 689 | 642 | |||||
| Total current liabilities | 26,797 | 22,360 | |||||
| Long-term deferred revenue | 384 | 555 | |||||
| Long-term contingent consideration | 5,343 | 4,724 | |||||
| Operating lease liabilities | 4,484 | 4,794 | |||||
| Other liabilities | 1,097 | 1,097 | |||||
| Total liabilities | 38,105 | 33,530 | |||||
| Series A - Convertible preferred stock: | |||||||
| Convertible preferred stock, Series A, par value | 5,234 | 5,240 | |||||
| Stockholders' equity: | |||||||
| Common stock, par value | 98 | 95 | |||||
| Additional paid-in capital | 606,048 | 596,960 | |||||
| Treasury stock, 4,015 shares at 2026 and 2025 | (206 | ) | (206 | ) | |||
| Accumulated deficit | (593,697 | ) | (583,368 | ) | |||
| Total stockholders' equity | 12,243 | 13,481 | |||||
| Total liabilities and stockholders' equity | $ | 55,582 | $ | 52,251 | |||
